JNJ-4804 Shows Strong Efficacy in Refractory IBD, Bolstering Immunology Pipeline

What happened

Johnson & Johnson presented Phase 2b data for its novel co-antibody JNJ-4804, which targets both IL-23 and TNF pathways, showing the highest rates of clinical and endoscopic outcomes in patients with refractory ulcerative colitis and Crohn's disease compared to existing therapies. This is the first antibody of its kind, and the data support advancement to Phase 3, addressing a critical unmet need. However, the near-term financial impact is minimal given the early stage, and the stock already prices in high single-digit ex-Stelara growth. The positive readout reinforces JNJ's immunology pipeline, central to offsetting Stelara's decline, but does not alter the current thesis that growth hinges on existing products like Tremfya and Carvykti.

Implication

The JNJ-4804 data strengthen the immunology pipeline and could contribute to long-term growth, but Phase 3 trials and approval are years away. Immediate risk-reward remains tied to execution on Tremfya, Carvykti, and talc litigation resolution. At current valuation, this news does not warrant a change in position; wait for a better entry point near $190 or clearer evidence of pipeline commercial viability.

Thesis delta

The Phase 2b data modestly de-risks the immunology pipeline, increasing the probability that JNJ can sustain growth beyond the Stelara and eventual Darzalex cliffs. However, the core thesis remains unchanged: near-term upside is limited at current prices, and the stock still requires perfect execution and benign legal outcomes. The news provides a slight tailwind to the bull case but does not shift the base-case fair value of ~$215.